Compare Stocks

→ World’s biggest multibillionaire investor is buying THIS by the ton [picture] (From Stansberry Research) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSD Clearside Biomedical	$1.26 -6.0%	$1.45	$0.65 ▼ $2.12	$94.15M	2.29	337,430 shs	135,239 shs
CTST CannTrust	C$0.64	C$0.64	C$0.38 ▼ C$8.17	C$90.27M	N/A	N/A	N/A
EPIX ESSA Pharma	$6.12 -2.1%	$8.39	$2.56 ▼ $11.67	$270.75M	1.62	135,637 shs	64,770 shs
OTIC Otonomy	$0.01	$0.06	$0.01 ▼ $2.54	$582K	1.54	937,525 shs	N/A
ZYNE Zynerba Pharmaceuticals	$1.30 +2.4%	$1.30	$0.25 ▼ $1.40	$70.12M	1.32	515,333 shs	862,700 shs

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSD Clearside Biomedical	-2.19%	+6.35%	-22.54%	+10.74%	+25.23%
CTST CannTrust	0.00%	0.00%	0.00%	0.00%	0.00%
EPIX ESSA Pharma	-2.34%	-11.60%	-30.86%	-8.09%	+133.21%
OTIC Otonomy	0.00%	0.00%	0.00%	0.00%	0.00%
ZYNE Zynerba Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+253.36%

World’s biggest multibillionaire investor is buying THIS by the ton [picture] (Ad)

Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.

Click here to find out what to do.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLSD Clearside Biomedical	2.4474 of 5 stars	3.5	3.0	0.0	0.0	2.5	1.7	0.6
CTST CannTrust	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	1.6658 of 5 stars	3.5	3.0	0.0	0.0	0.0	3.3	0.0
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSD Clearside Biomedical	3.00	Buy	$4.75	276.98% Upside
CTST CannTrust	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	3.00	Buy	$16.50	169.61% Upside
OTIC Otonomy	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	2.00	Hold	$1.11	-14.62% Downside

Current Analyst Ratings

Latest OTIC, EPIX, ZYNE, CTST, and CLSD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
3/14/2024	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/13/2024	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
3/13/2024	CLSD Clearside Biomedical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $4.00

(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSD Clearside Biomedical	$8.23M	11.44	N/A	N/A	($0.25) per share	-5.04
CTST CannTrust	C$35.22M	2.56	N/A	N/A	N/A	∞
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	$3.30 per share	N/A
OTIC Otonomy	$130K	4.48	N/A	N/A	$0.97 per share	0.01
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	$1.01 per share	N/A

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSD Clearside Biomedical	-$32.49M	-$0.53	N/A	N/A	N/A	-394.91%	N/A	-85.31%	5/9/2024 (Estimated)
CTST CannTrust	-C$10.46M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	-$26.58M	-$0.59	N/A	N/A	N/A	N/A	-17.41%	-17.04%	5/14/2024 (Estimated)
OTIC Otonomy	-$51.18M	-$0.77	N/A	∞	N/A	N/A	-137.86%	-68.50%	N/A
ZYNE Zynerba Pharmaceuticals	-$35.04M	-$0.80	N/A	N/A	N/A	N/A	-90.03%	-72.62%	N/A

Latest OTIC, EPIX, ZYNE, CTST, and CLSD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q4 2023	CLSD Clearside Biomedical	-$0.10	-$0.08	+$0.02	-$0.08	$3.40 million	$6.35 million
2/13/2024	12/31/2023	EPIX ESSA Pharma	-$0.17	-$0.14	+$0.03	-$0.14	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CTST CannTrust	N/A	N/A	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A
ZYNE Zynerba Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSD Clearside Biomedical	N/A	4.42	4.42
CTST CannTrust	N/A	N/A	N/A
EPIX ESSA Pharma	N/A	40.74	40.74
OTIC Otonomy	N/A	1.74	1.74
ZYNE Zynerba Pharmaceuticals	N/A	3.43	3.43

Ownership

Institutional Ownership

Company	Institutional Ownership
CLSD Clearside Biomedical	18.75%
CTST CannTrust	0.03%
EPIX ESSA Pharma	75.12%
OTIC Otonomy	41.23%
ZYNE Zynerba Pharmaceuticals	11.23%

Insider Ownership

Company	Insider Ownership
CLSD Clearside Biomedical	9.80%
CTST CannTrust	N/A
EPIX ESSA Pharma	14.70%
OTIC Otonomy	1.09%
ZYNE Zynerba Pharmaceuticals	13.04%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSD Clearside Biomedical	30	74.72 million	67.40 million	Optionable
CTST CannTrust	576	141.49 million	N/A	Optionable
EPIX ESSA Pharma	50	44.24 million	37.74 million	Optionable
OTIC Otonomy	51	68.53 million	67.78 million	Optionable
ZYNE Zynerba Pharmaceuticals	25	53.94 million	46.91 million	Optionable

OTIC, EPIX, ZYNE, CTST, and CLSD Headlines

Source	Headline
	Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results finance.yahoo.com - October 31 at 7:57 AM
	Why Shares of Harmony Bioscience Are Falling on Friday fool.com - October 13 at 12:59 PM
	New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies markets.businessinsider.com - October 11 at 9:47 AM
	HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE finance.yahoo.com - October 11 at 9:47 AM
	H.C. Wainwright analysts reiterates a Buy rating for Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 10 at 1:59 PM
	Analysts: ZYNE stock price target of $1.25 in 12 months knoxdaily.com - October 5 at 6:47 PM
	Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions finance.yahoo.com - October 4 at 7:33 PM
	Examining the Potential Price Growth of Zynerba Pharmaceuticals Inc (ZYNE) knoxdaily.com - October 2 at 3:14 PM
	20 Countries With Highest Rate of Epilepsy finance.yahoo.com - September 29 at 6:24 PM
	Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023 finance.yahoo.com - September 29 at 1:23 PM
	Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal bizjournals.com - September 27 at 2:42 PM
	Zynerba Pharmaceuticals Inc [ZYNE] Investment Appeal on the Rise knoxdaily.com - September 25 at 8:15 PM
	Zynerba Pharmaceuticals Inc. (ZYNE) rating reiterates by H.C. Wainwright knoxdaily.com - September 20 at 12:12 PM
	Negative sentiment towards ZYNE reflected in surge in short interest knoxdaily.com - September 15 at 8:27 PM
	Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc finance.yahoo.com - September 14 at 11:23 PM
	Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium finance.yahoo.com - September 14 at 6:23 PM
	Zynerba Pharmaceuticals Hit With Shareholder Suit in Pa. Over Allegedly Inadequate Proxy Statement law.com - September 11 at 4:04 PM
	Positive sentiment towards ZYNE reflected in decline in short interest knoxdaily.com - September 8 at 5:19 AM
	SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CTG, ZYNE, KLR bakersfield.com - August 31 at 5:00 PM
	HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE) msn.com - August 16 at 4:20 AM
	Harmony Makes Rare Disease Play with Potential $200M Zynerba Buyout biospace.com - August 15 at 6:19 PM
	Zynerba Pharma (NASDAQ: ZYNE) up 300% - The contingents are worth how much? dhakatribune.com - August 15 at 6:19 PM
	Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans? finance.yahoo.com - August 15 at 6:19 PM
	Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNE marketwatch.com - August 14 at 9:48 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
3 Computer Vision Stocks for Long-Term Gains From AI
April 16, 2024 6:08 AM
View 3 Computer Vision Stocks for Long-Term Gains From AI
Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
April 10, 2024 7:55 AM
View Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
Intuitive Surgical Leads the Robotic Surgery Movement
April 22, 2024 6:10 AM
View Intuitive Surgical Leads the Robotic Surgery Movement

All Headlines

Company Descriptions

Clearside Biomedical

NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

CannTrust

NYSE:CTST

CannTrust Holdings Inc. produces and sells medical and recreational cannabis in Canada. It sells dried cannabis and cannabis extracts to the medical patients. CannTrust Holdings Inc. was incorporated in 2015 and is headquartered in Vaughan, Canada.

ESSA Pharma

NASDAQ:EPIX

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Otonomy

NASDAQ:OTIC

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Zynerba Pharmaceuticals

NASDAQ:ZYNE

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial